Lambutrix (Lorazepam)

Lorazepam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor, increasing chloride ion flow into neurons, which reduces neuronal excitability and produces calming, sedative, muscle‑relaxant, and anticonvulsant effects.

The appropriate dose of Lambutrix is determined by the prescribing clinician based on the patient’s condition, age, weight, and response. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety of lorazepam in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To order Lambutrix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Lambutrix (lorazepam) offers a relatively long duration of action and a predictable pharmacokinetic profile compared with shorter‑acting agents like midazolam. Its potency and safety profile make it suitable for both acute anxiety relief and seizure control, though choice of agent depends on clinical context.

Lambutrix should be stored at 2‑8 °C, kept refrigerated, protected from light, and should not be frozen. Maintain the product in its original packaging to preserve stability.

Lambutrix is administered by a healthcare professional via intramuscular or intravenous injection, following aseptic technique. The route and rate of administration are determined by the clinical indication and patient condition.

Serious risks include respiratory depression, severe hypotension, paradoxical reactions such as aggression, anaphylaxis, and rare skin reactions like Stevens‑Johnson syndrome. Immediate medical attention is required if any of these occur.

Lambutrix is contraindicated in patients with known hypersensitivity to lorazepam or other benzodiazepines, those with acute narrow‑angle glaucoma, and individuals who are currently abusing alcohol or other CNS depressants without medical supervision.